4th Quarter - Report — CEPHEID for CEPHEID (2014)

Firm

CEPHEID

Client

CEPHEID

Income

—

Expenses

$50,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

See page threeLobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
HALLIE CHRISTINE LEWIS	—
MICHELE M SCHOONMAKER	—

Contacted: Food & Drug Administration (FDA); SENATE; Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ)

Medicare/Medicaid MMM

See page 7Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
HALLIE CHRISTINE LEWIS	—
MICHELE M SCHOONMAKER	—

Contacted: Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); Medicare Payment Advisory Commission (MedPAC); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ)

Medical/Disease Research/Clinical Labs MED

See page fiveLobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
HALLIE CHRISTINE LEWIS	—
MICHELE M SCHOONMAKER	—

Contacted: Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; SENATE; Centers For Disease Control & Prevention (CDC); Agency for Healthcare Research & Quality (AHRQ); Medicare Payment Advisory Commission (MedPAC); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.